340 related articles for article (PubMed ID: 19294001)
1. Insights into endometrial serous carcinogenesis and progression.
Fadare O; Zheng W
Int J Clin Exp Pathol; 2009; 2(5):411-32. PubMed ID: 19294001
[TBL] [Abstract][Full Text] [Related]
2. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
3. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
[TBL] [Abstract][Full Text] [Related]
4. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
Liang SX; Chambers SK; Cheng L; Zhang S; Zhou Y; Zheng W
Int J Surg Pathol; 2004 Oct; 12(4):319-31. PubMed ID: 15494858
[TBL] [Abstract][Full Text] [Related]
5. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
6. Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers.
Fadare O; Zheng W
Diagn Pathol; 2008 Feb; 3():6. PubMed ID: 18261213
[TBL] [Abstract][Full Text] [Related]
7. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.
Romero-Pérez L; López-García MÁ; Díaz-Martín J; Biscuola M; Castilla MÁ; Tafe LJ; Garg K; Oliva E; Matias-Guiu X; Soslow RA; Palacios J
Mod Pathol; 2013 Nov; 26(11):1514-24. PubMed ID: 23743934
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 expression in endometrial serous carcinomas and its precancers.
Chen N; Yi X; Abushahin N; Pang S; Zhang D; Kong B; Zheng W
Int J Clin Exp Pathol; 2010 Dec; 4(1):85-96. PubMed ID: 21228930
[TBL] [Abstract][Full Text] [Related]
9. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
10. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
[TBL] [Abstract][Full Text] [Related]
11. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
12. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
13. A proposed model for endometrial serous carcinogenesis.
Zheng W; Xiang L; Fadare O; Kong B
Am J Surg Pathol; 2011 Jan; 35(1):e1-e14. PubMed ID: 21164282
[TBL] [Abstract][Full Text] [Related]
14. Serous endometrial intraepithelial carcinoma arising in adenomyosis: a report of 5 cases.
Abushahin N; Zhang T; Chiang S; Zhang X; Hatch K; Zheng W
Int J Gynecol Pathol; 2011 May; 30(3):271-81. PubMed ID: 21464726
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
16. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
17. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
[TBL] [Abstract][Full Text] [Related]
19. Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.
Lu B; Chen Q; Zhang X; Cheng L
Diagn Pathol; 2016 Jun; 11(1):46. PubMed ID: 27260518
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
